Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

First-line treatment of ovarian cancer: questions and controversies to address:

First-line treatment of ovarian cancer: questions and controversies to address: 768232 TAM0010.1177/1758835918768232Therapeutic Advances in Medical OncologyJA Ledermann editorial20182018 Therapeutic Advances in Medical Oncology Editorial Ther Adv Med Oncol First-line treatment of ovarian cancer: 2018, Vol. 10: 1 –8 https://doi.org/10.1177/1758835918768232 DOI: 10.1177/ https://doi.org/10.1177/1758835918768232 questions and controversies to address © The Author(s), 2018. Reprints and permissions: http://www.sagepub.co.uk/ Jonathan A. Ledermann journalsPermissions.nav Introduction There is little doubt that the survival of women laparotomy fall into a better group responding for Correspondence to: Jonathan A. Ledermann with advanced ovarian cancer has improved over longer to chemotherapy. Progression-free survival UCL Cancer Institute, the last two decades. Platinum and paclitaxel are (PFS) differences in groups with no residual dis- Cancer Research UK and UCL Cancer Trials Centre, the two key drugs that have now been in standard ease or any residual disease are large which can 90 Tottenham Court Road, use for over 20 years. This followed the results of make interpretation of the additional value of London W1T 4TJ, UK j.ledermann@ucl.ac.uk; two large-scale trials with more than 6 years of newer systemic treatments more complex; the UCL Cancer Institute, follow up that demonstrated an 11% advantage in amount of tumour residuum has been an impor- University College London, London, UK survival with cisplatin-paclitaxel compared http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Therapeutic Advances in Medical Oncology SAGE

First-line treatment of ovarian cancer: questions and controversies to address:

First-line treatment of ovarian cancer: questions and controversies to address:

Therapeutic Advances in Medical Oncology , Volume 10: 1 – Apr 11, 2018

Abstract

768232 TAM0010.1177/1758835918768232Therapeutic Advances in Medical OncologyJA Ledermann editorial20182018 Therapeutic Advances in Medical Oncology Editorial Ther Adv Med Oncol First-line treatment of ovarian cancer: 2018, Vol. 10: 1 –8 https://doi.org/10.1177/1758835918768232 DOI: 10.1177/ https://doi.org/10.1177/1758835918768232 questions and controversies to address © The Author(s), 2018. Reprints and permissions: http://www.sagepub.co.uk/ Jonathan A. Ledermann journalsPermissions.nav Introduction There is little doubt that the survival of women laparotomy fall into a better group responding for Correspondence to: Jonathan A. Ledermann with advanced ovarian cancer has improved over longer to chemotherapy. Progression-free survival UCL Cancer Institute, the last two decades. Platinum and paclitaxel are (PFS) differences in groups with no residual dis- Cancer Research UK and UCL Cancer Trials Centre, the two key drugs that have now been in standard ease or any residual disease are large which can 90 Tottenham Court Road, use for over 20 years. This followed the results of make interpretation of the additional value of London W1T 4TJ, UK j.ledermann@ucl.ac.uk; two large-scale trials with more than 6 years of newer systemic treatments more complex; the UCL Cancer Institute, follow up that demonstrated an 11% advantage in amount of tumour residuum has been an impor- University College London, London, UK survival with cisplatin-paclitaxel compared

Loading next page...
 
/lp/sage/first-line-treatment-of-ovarian-cancer-questions-and-controversies-to-cih3wu9ehy

References (37)

Publisher
SAGE
Copyright
Copyright © 2022 by SAGE Publications Ltd unless otherwise noted. Manuscript content on this site is licensed under Creative Commons Licenses
ISSN
1758-8340
eISSN
1758-8359
DOI
10.1177/1758835918768232
Publisher site
See Article on Publisher Site

Abstract

768232 TAM0010.1177/1758835918768232Therapeutic Advances in Medical OncologyJA Ledermann editorial20182018 Therapeutic Advances in Medical Oncology Editorial Ther Adv Med Oncol First-line treatment of ovarian cancer: 2018, Vol. 10: 1 –8 https://doi.org/10.1177/1758835918768232 DOI: 10.1177/ https://doi.org/10.1177/1758835918768232 questions and controversies to address © The Author(s), 2018. Reprints and permissions: http://www.sagepub.co.uk/ Jonathan A. Ledermann journalsPermissions.nav Introduction There is little doubt that the survival of women laparotomy fall into a better group responding for Correspondence to: Jonathan A. Ledermann with advanced ovarian cancer has improved over longer to chemotherapy. Progression-free survival UCL Cancer Institute, the last two decades. Platinum and paclitaxel are (PFS) differences in groups with no residual dis- Cancer Research UK and UCL Cancer Trials Centre, the two key drugs that have now been in standard ease or any residual disease are large which can 90 Tottenham Court Road, use for over 20 years. This followed the results of make interpretation of the additional value of London W1T 4TJ, UK j.ledermann@ucl.ac.uk; two large-scale trials with more than 6 years of newer systemic treatments more complex; the UCL Cancer Institute, follow up that demonstrated an 11% advantage in amount of tumour residuum has been an impor- University College London, London, UK survival with cisplatin-paclitaxel compared

Journal

Therapeutic Advances in Medical OncologySAGE

Published: Apr 11, 2018

There are no references for this article.